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A B S T R A C T
Objective: To identify associations between circulating endocannabinoids and craving during the luteal phase of
the menstrual cycle. This report is a secondary analysis of a trial registered in clinicaltrials.gov as NCT01407692.
Methods: Seventeen premenopausal women were studied during the follicular and luteal phases of their men-
strual cycle. Previously we had reported fasting plasma estradiol, progesterone, leptin associations with luteal
phase cravings for carbohydrate, fat, sweet-rich foods, and eating behavior. Here, we measured fasting plasma
endocannabinoids (ECs) endocannabinoid-like substances (ECLs), and postprandial metabolic responses to a
mixed meal challenge. Structural equation modeling was used to evaluate relationships between measured
variables and cravings.
Results: Oleoylethanolamide (OEA) and postprandial lipids were inversely associated with craving sweet-rich
foods, while progesterone was positively associated (RMSEA=0.041, χ2 p: 0.416 i.e. hypothetical and phy-
siological models not different). OEA, progesterone and disinhibition were positively associated with craving
carbohydrates (RMSEA:<0.001, χ2 p: 0.919). ECs and ECLs combined were stronger predictors of craving than
clinical metabolic parameters, ECs only, satiety hormones or gonadocorticoids.
Conclusions: Our theoretical model suggests that ECs and ECLs influence craving. Since these metabolites can be
modulated via dietary fat intake, they could be potential targets to alter menstrual cycle cravings.
Clinical Trial Registration Number: NCT01407692
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1. Introduction
Food intake regulation is a crucial component of body weight con-
trol. Satiety and appetite-modulating endocrine and central nervous
system circuits determine food intake. Endocannabinoids (ECs) are lipid
mediators that include amides, esters and ethers of polyunsaturated
fatty acids (PUFAs) that are endogenous ligands of the cannabinoid
receptors [1], with myriad functions including the regulation of eating
and craving behaviors [2–4]. Moreover, the satiety hormone leptin has
been shown to suppress hypothalamic EC levels following acute ad-
ministration in mice [5]. The most well studied ECs are the arachido-
nate-derived ananadamide or N-arachidonoylethanolamide (AEA) and
2-arachidonoylglycerol (2-AG) [6]. In addition, several structurally si-
milar N-acylethanolamide- (NAE) and monoacylglycerol- (MAG) deri-
vatives of PUFAs (collectively referred to as endocannabinoid-like
substances or ECLs) exist [7].
Signaling in the endocannabinoid system is complex. ECs and ECLs
bind to several receptors with different degrees of affinity, inducing
multifaceted physiological effects [8, 9]. AEA and 2-AG, along with
several NAEs (e.g. docosahexenoylethanolamide, DHEA and eicosa-
pentenoylethanolamide, EPEA), bind to cannabinoid receptors 1 and 2
(CB1/2), both in the brain and peripheral tissues [7]. 2-oleoylglycerol
(2-OG) and oleoylethanolamide (OEA) are poor CB1/2 ligands, but
induce their effects by binding to PPARα, or other G-protein coupled
receptors (GPCRs) [7]. For instance, OEA, linoleoylethanolamide (LEA)
and OGs are potent agonists of the orphaned GPR119 [10], activation of
which stimulates incretin hormone release in response to meals [11].
The luteal phase of the menstrual cycle is associated with strong
food cravings, especially for sweet-, carbohydrate- and fat-rich foods,
contributing to higher energy intake and weight gain over time [12,
13]. In a previous study, referred to henceforth as ‘our previous report’,
we investigated the metabolic underpinnings of cravings focused on
whether the primary ovarian hormones, estradiol and progesterone, as
well as leptin were associated with craving for sweet, fat and carbo-
hydrate rich foods [14]. This is a follow-up ancillary study which has
added additional measures (endocannabinoid system, clinical responses
to a standard mixed meal challenge test) and a novel approach (feature
selection followed by covariance based structural equation modeling)
to evaluate factors that predict craving behaviors using the same re-
search cohort [14]. In particular, we evaluate eating behaviors that
include cognitive restraint, i.e. a “tendency to consciously restrict or
control food intake” and disinhibition, i.e. a “tendency to overeat in the
presence of palatable foods or other stimuli such as stress” which have
been strongly associated with weight gain and higher BMI in women
[15].
The primary objective of the current study was to identify factors
strongly/causally related to craving behaviors, while accounting for
their inter-relational covariance, amidst a milieu of metabolic, an-
thropometric, endocrine and cognitive components. Here, we use
structural equation modeling (SEM), to explore the relationships be-
tween ECs, ECLs, eating behaviors and clinical measures as predictors
of craving in the luteal phase of the menstrual cycle. The SEM is used as
a hypothesis generating tool, creating a theoretical framework of as-
sociations between the endocannabinoid, gonadal and satiety hormone




This is an observational study of the follicular and luteal phases of
the menstrual cycle details of which can be found in our previous re-
port, including descriptive statistics about our participants [14].
Briefly, healthy women between the ages of 18–45 y, with regular
menstrual cycles, not on hormonal contraceptives women were studied
twice during their menstrual cycle, once during the late follicular
phase, and once in the mid-late luteal phase. Further details about this
questionnaire, and its scoring are discussed in detail in our previous
report [14]. The study was approved by the Institutional Review Board
of the University of California Davis, and all participants signed an
informed consent form at enrolment. This study is registered on
ClinicalTrails.gov as NCT01407692
2.2. Standard meal challenge
On the scheduled test day, participants arrived at the test center
following an overnight fast, to consume a standardized breakfast
(08:00) and lunch (11:30). Blood was collected at three time points –
upon arrival (fasting), 1 h after lunch (1hPP), and 2 h after lunch
(2hPP). The postprandial blood draws were done following lunch to
avoid the second meal effect from their self-selected meals the previous
night (Supplementary Table 1).
2.3. Clinical markers
Plasma insulin, glucose, triglycerides, total cholesterol, LDL-c and
HDL-c were measured at the fasting and two postprandial time points.
Plasma glucose and lipids were measured using chemiluminescence
technology on a Clinical Chemistry Analyser (COBAS Integra 400+,
Roche Diagnostics Corp., Indianapolis, IN). Fasting and postprandial
plasma insulin and fasting plasma leptin, serum estradiol and proges-
terone were measured using electro-chemiluminescence on a Sector
Imager 2400 (Model 1250, Meso-Scale Discovery, Gaithersburg, MD).
The fasting serum was used to measure DHEAS (dehydroepian-
drosterone-sulphate), which was also measured using chemilumines-
cence on the COBAS Integra 400+ (Roche). Sex hormone binding
globulin (SHBG) was measured using a Quantikine (R) ELISA kit
(Minneapolis, MN). The fasting values were previously reported in our
primary manuscript as outcomes [14].
2.4. Questionnaires
The food craving inventory, created and validated by White et al.
[14], was used to obtain responses from participants during the luteal
phase, about cravings for fat-rich, sweet-tasting and carbohydrate rich
foods. Briefly, the questionnaire includes lists of foods that belong to 5
different categories – sweets, high fat, starches/carbohydrate, fast foods
and sweet beverages. Participants scored their craving for each of them
during the luteal phase testing on a likert scale ranging from never to
daily. Scores were totaled per category and used as a measure of craving
each food type. The Eating Inventory was administered at screening to
all women enrolled in the study. This instrument is the commercially
available version of the Three Factor Eating questionnaire [16], and has
been established and validated by Stunkard AJ and Messick S. The
questionnaire asked participants about their eating behaviors, and
provided scores for three dimensions of eating behaviors – cognitive
restraint, disinhibition and hunger.
2.5. Measurement of Endocannabinoids and endocannabinoid-like
substances measurement
ECs and ECLs were isolated from fasting serum collected on both
test days using modifications of a previously published protocol [17,
18]. Briefly, 100 μL aliquots of serum were enriched with 10 μL of 1 μM
deuterated analytical surrogates [18, 19], after which 5 μL of an anti-
oxidant solution (0.2 mg/mL butylated hydroxytoluene/EDTA in 1:1
methanol:water) and 300 μL acetonitrile with 1% formic acid was
added to each sample. Samples were extracted by elution through an
Ostro Sample Preparation Plate (Waters Corp., Milford, MA), and the
eluent was dried by vacuum evaporation and reconstituted in 100 μL of
an internal standard solution containing 100 nM each of 1-cyclohexyl-
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3-ureido dodecanoic acid (Sigma Aldrich, St. Louis, MO) and 1-
phenyl,3-ureido hexanoic acid (gift from B. D. Hammock, University of
California-Davis) in 1:1 (v/v) methanol/acetonitrile.
Quantification of extracted ECs and ECLs using targeted ultra-per-
formance liquid chromatography coupled to tandem mass spectrometry
was conducted using a previously published method [18, 19]. Briefly,
analytes were separated on a 2.1×150mm, 1.7 μm BEH C18 column
(Waters) and detected by positive mode electrospray ionization tandem
mass spectrometry on an API 4000 QTRAP (Sciex, Framingham, MA).
Analytes were quantified by internal standard methodology using five
to seven point calibration curves (r≥ 0.997) and data were processed
in MultiQuant v3.0.2 (Sciex). All calibration standards and analytical
surrogates were purchased from Cayman Chemical (Ann Arbor, MI) or
Avanti Polar Lipids Inc. (Alabaster, AL).
Measured analytes included monoacylglycerol derivatives of ara-
chidonate, linoleate and oleate (1- and 2-AG, LG and OG, respectively),
and the acylethanolamide derivatives of arachidonate, oleate, doc-
osatetraenoate, docosahexaenoate, alpha-linolenate and dihomo-
gamma-linoleate (AEA, OEA, DEA, DHEA, aLEA and DGLEA, respec-
tively).
2.6. Statistical analysis
Data analysis was done in R (R statistical software, Vienna Austria
[20]) using packages nlme, lavaan, and semPlot, and JMP Pro 13.1 (SAS
Institute, Cary, NC). Preliminary differences between the luteal and
follicular phase fasting variables have been presented in our previous
report [14]. The newly measured meal challenge response variables,
endocannabinoids, and previously reported TFEQ and FCI scores were
tested for normality using Shapiro-Wilk test. Grubbs test was used to
detect outliers and none were found. Since data were not normally
distributed, non-parametric tests were used unless specified otherwise.
Wilcoxon's rank tests were used to identify differences between phases
in endocannabinoids and eating behavior factors. Lipids, glucose and
insulin responses to the standard meal challenge responses were log
transformed, and phase differences were evaluated using linear mixed
model analysis, with participant as the random effect, and time of blood
draw as the repeated factor. Spearman's correlations were used to
identify associations between ovarian hormones, endocannabinoids and
leptin, irrespective of phase.
2.7. Feature selection and structural equation modeling
Data were range scaled prior to analysis [21], since SEM is vul-
nerable to differences in magnitude and scale across multiple variables
[22]. Since the degrees of freedom for an analysis where n=17 is
small, the number of variables that can be entered as independent or
latent variables in the SEM is limited. Hence, we performed feature
selection prior to building SEMs. Feature selection was accomplished
using cluster analysis (eigenvectors used to derive Euclidean distance),
which identified groups of correlated and co-linear variables. This was
used for both clinical data (fasting and postprandial responses to the
standard meal challenge test), as well as endocannabinoids (combined
ECs and ECLs). Cluster analysis grouped variables together that were
most correlated with each other in each phase (based on R2). A single
representative variable from each cluster was chosen for use in the
model because it displayed the highest correlation with the other
variables in that cluster explained the highest proportion of variation
within that cluster, and was also the least correlated with the neigh-
boring cluster. Cluster analysis was not used to identify representative
variables from eating behaviors or ovarian hormones because it was
possible to include all of them without needing a larger sample size.
Rather, variable inclusion was decided based on statistical fitness of the
final model. Hence, to build the SEM models, the following variables
were used: representative variables chosen by cluster analysis of clinical
data and ECLs; eating behaviors (hunger score, cognitive restraint and
disinhibition); and ovarian/satiety hormones (estradiol, progesterone,
SHBG and leptin) [R code is available in Supplemental Material]. Models
were built backwards by elimination until model convergence, to
identify the best fit, retaining ideal variable(s) possible while also im-
proving chi square p-value. The FCI was only administered during the
luteal phase testing to capture craving tendencies for that phase.
However, we used both follicular and luteal phase clinical and endo-
crine milieu to predict craving during the luteal phase. It is possible that
craving in the luteal phase is a result of the lead-in milieu set up during
the follicular phase, due to current luteal phase milieu, and the change
between the two phases. Also, the craving inventory that was ad-
ministered during the luteal phase was used to ask participants about
their cravings during the two-week period leading up to the luteal
phase test day. This is an approximate two-week period immediately
following the follicular phase testing. This adds further support for our
hypothesis that the follicular phase milieu could set-up the cravings
experienced during the luteal phase. Hence, luteal phase craving for
sweet-, carbohydrate- and fat-rich foods were predicted independently
using follicular phase and luteal phase endocannabinoids, clinical,
eating behavior and, ovarian and satiety hormones.
The SEM predicts a dependent variable, in this case craving, using
latent variables or factors modeled from the measured inputs. SEM
includes a confirmatory factor analysis that identifies latent variables or
factors that best represent measured variables, combined with a path
analysis to identify potential causal relationships between the identified
latent variables/factors and the outcome variable. The following latent
variables were generated for our craving model: Endocannabinoids
representing ECs and ECLs; Clinical variables representing clinical
fasting and postprandial variables; Eating behaviors representing -
cognitive restraint, hunger score and disinhibition; Ovarian/Satiety
hormones representing estradiol, sex hormone binding globulin
(SHBG), progesterone, DHEAS and leptin. Model fit, power and ro-
bustness were evaluated rigorously using several indices [22–24]. The
Tucker-Lewis Index (TLI) and Comparative Fit Index (CFI) are model fit
estimators, ranging between 0 and 1, with a number closer to 1 con-
sidered a better fit for the model. However, if the CFI is 1, the TLI can
be>1 indicating a very good model fit. The modification index pro-
vides a measure of model sensitivity to variable inclusion. Modification
indices of< 3.84 for individual correlation and covariance is con-
sidered a good fit. The Root Mean Square Error of Approximation
(RMSEA) is habitually used in SEM to evaluate overall model power
and robustness. An RMSEA of< 0.02, 0.02–0.08 and > 0.08 are used
to designate excellent, fair and poor model fits respectively. Finally, a
chi-square (χ2) test was used to compare the model outcome to the FCI
measured craving scores. A p-value of> 0.05 indicates the predicted
scores are not significantly different from those measured, and there-
fore represent a well fit SEM model.
In the Figures that depict the SEM models (Figs. 2–4), measured
variables are represented by a rectangle or square box, and latent (or
unmeasured) factors by a circle or ellipse [24]. Single headed arrows or
‘paths’ are used to define causal relationships in the model and positive
or negative coefficients are indicated by (+) and (−) symbols next to
the arrows. Double-headed arrows indicate covariances or correlations
(solid black lines indicate positive, and dashed black lines indicate in-
verse) that are a priori declared while building the model, without a
causal interpretation. Statistically, the single headed arrows or paths
represent regression coefficients, and double-headed arrows covar-
iances. There is no assumption that the latent factors completely ex-
plain observed variation in the outcome variable. In addition, the as-
sociations between each variable (measured and latent) take into
consideration the covariance and inter-correlation matrix of the data
array. Hence, each figure represents a holistic picture of their inter-
relationships, as opposed to independent correlations.
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3. Results
3.1. Meal challenge and endocannabinoids between the phases
Insulin was significantly higher at 2 h postprandial in the follicular
phase compared to the luteal phase (p < .001). No phase differences
were found in fasting or postprandial triglycerides, total cholesterol,
LDL or HDL cholesterol, and glucose following the standard meal
challenge (Supplementary Table 2). There were no differences in the
ECs or ECLs between the two phases (Supplementary Table 3).
3.2. Correlational analysis
Estradiol was inversely associated with MAGs (2-OG: r=−0.753,
p= .02, 2-AG: r=−0.677, p= .09) (Fig. 1). Additionally, SHBG was
inversely associated with ECLs (2-LG: r=−0.681, p= .09, aLEA:
r=−0.841, p= .01, LEA: r=−0.770, p= .02), as was leptin (OEA:
r=−0.451, p= .08, DHEA: r=−0.512, p= .06).
3.3. Feature selection
The cluster analysis grouped the clinical variables into six clusters in
the follicular and luteal phases. ECLs were split into two clusters in both
phases, while ovarian and satiety hormones were split into two clusters
in follicular phase and 3 clusters in the luteal phase (Supplementary
Fig. 1).
3.4. Structural equation modeling
Table 1 outlines the evaluation of the model fit, for each phase, for
predicting cravings for sweet-tasting and carbohydrate-rich foods that
were a fair, good or excellent fit, and were able to predict craving.
Supplemental Table 4 outlines the models that were poorly fit. The
models were built to predict craving experienced during the luteal
phase, as a result of either follicular phase or luteal phase milieu. It is of
interest to note that both AEA and 2AG were used in building the
ECs+ECLs models, but 2-AG consistently weakened the model fit
within this paradigm. Three models that matched the criteria to accept
the fit based on RMSEA, TLI, CFI, chi square p value and modification
indices are graphically represented in Figs. 2–4.
The model depicted in Fig. 2 evaluates the impact of ECLs, ovarian
hormones, fasting and postprandial metabolic parameters and eating
behaviors in the follicular phase on craving carbohydrate rich foods in
the luteal phase. ECLs (OEA), ovarian hormones (progesterone) and
eating behavior (disinhibition) were positively associated with craving
behavior as indicated by the positive estimates. This association in-
dicates that higher OEA and progesterone in the follicular phase and
overall higher disinhibition are associated with increased craving for
carbohydrates. Clinical parameters following the standard meal chal-
lenge in the follicular phase did not appear to play a significant role in
craving carbohydrate-rich foods in the luteal phase.
The model depicted in Fig. 3 evaluates the effect of ECLs, ovarian
hormones, fasting and postprandial metabolic parameters and eating
behaviors in the follicular phase on craving sweet foods during the
luteal phase. ECLs, ovarian/satiety hormones (progesterone) and eating
behaviors (disinhibition) were positively associated, clinical parameters
(2hPP TG, fasting glucose, 1hPP HDL) were inversely associated with
craving. Curiously, while lipid clinical parameters appear to contribute
inversely to the latent clinical variable construct, some of the glucose
and insulin parameters contribute positively to it, despite the overall
contribution to craving by clinical parameters being negative. Simi-
larly, OEA appears to contribute inversely to the latent en-
docannabinoids factor/variable construct, even though ECLs as a whole
positively contributes to sweet-craving.
The model depicted in Fig. 4 is very similar to the one in Fig. 3, with
the only exception that it includes ECs as measured follicular phase
variables. Hence, it evaluates the effect of ECs, ECLs, ovarian hormones,
fasting and postprandial metabolic parameters and eating behaviors in
the follicular phase on craving sweet foods in the luteal phase. ECLs
(OEA), ECs (AEA) and clinical metabolic parameters (2 h PP TC), were
associated with craving sweet tasting foods. Curiously, 2hPP TC and
OEA inversely contributed to the latent variable.
Fig. 1. The Spearman's rank correlation analyses ir-
respective of phase for hormones and en-
docannabinoids (i.e. using data from both phases)
are presented. The color scale orange and purple are
used to indicate positive and inverse associations
respectively that show a trend (0.1 > p > .05, rho:
(+/−) 0.29–0.33) or are significant (p < .05,
rho:> (+/−) 0.34) in an n=17 women.
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Finally, none of the models predicting fat craving were fit well and
did not pass our robustness and rigor tests, as seen in Supplementary
Table 4.
4. Discussion
In this report we examined circulating ovarian and satiety hor-
mones, eating behaviors, an array of endocannabinoids and en-
docannabinoid-like-compounds as well as clinical metabolic parameters
to gain insight into the metabolic underpinnings of food cravings. In our
model testing, ECs alone were not adequate predictors of craving sweets
and carbohydrates; but the combination of ECs and ECLs were best able
to predict craving. An important result of the modeling building de-
monstrates that ECs and ECLs, as well as progesterone during the fol-
licular phase appear to be better at predicting craving sweet- and car-
bohydrate-rich foods in the luteal phase. AEA and certain MAGs (1-LG,
1-OG) are positively associated with craving sweet-rich and carbohy-
drate rich foods. OEA appears to be inversely associated with craving
sweets, while being positively associated with craving carbohydrates in
the luteal phase.
Our SEM analyses suggest that endocannabinoids are positively
associated with craving, both carbohydrate-rich and sweet-tasting
foods, primarily driven by AEA, NAEs (represented by OEA) and MAGs
(represented by 1-LG). AEA being positively associated with craving
sweet-rich foods is not surprising, since several studies have reported
the increase in sweet-taste liking, and consumption of palatable foods
by ECs [25–27]. Endocannabinoids induce hyperphagic responses via
activation of CB1 receptors [28, 29], and both MAGs and NAEs express
pharmacological effects via CB1/CB2 receptors as well [30].
Among ECLs, OEA was found to be positively associated with car-
bohydrate-rich food craving, while being inversely associated with
sweet food craving. ECLs are much less understood relative to ECs [29].
Several NAEs, especially OEA, modulate activation of GPR119 [10, 11],
a fat sensor in enteroendocrine and pancreatic beta cells [31]. This
modulation of GPR119 has been suspected to impact activation of GLP-
1, an incretin satiety hormone [32], reducing overall food intake in
rodents. It is likely that this pathway plays a role in the inverse asso-
ciation of OEA with sweet-food craving. However, the dichotomy be-
tween carbohydrate and sweet-food craving and OEA warrants further
study, possibly due to different neuro-endocrine mechanisms at play
that are yet to be understood.
Metabolic pathways impacting food intake and cravings change
from the fasted to the fed state [33]. Lipids in the postprandial state can
reduce desire to eat and cravings in a fed state, especially via chole-
cystokinin [34] as well as by mechanoreceptors activated by abdominal
distension [35]. Our SEM models agree with this ideology, and display
their (2hPP TG, 1hPP HDL, 2hPP TC) inverse association with craving
sweet-tasting foods.
The addition of ECs to the model predicting sweet-food craving
(that originally was tested with ECLs only) reversed or negated the
association of the latent clinical and eating behavior variables with
craving sweet foods (Fig. 3 vs 4). Since ECs can strongly influence
craving sweet-rich foods, we theorize that ECs and ECLs together may
be potent enough that other physiological factors may be relatively less
potent.
Ovarian/satiety hormones, represented by progesterone and SHBG
Table 1
SEM model fit parameters predicting sweet food, and fat-rich food craving during the luteal phase, using the luteal phase milieu, and the lead-in follicular phase











Model acceptability based on all
validation parameters (Excellent,
fair, poor)
Follicular phase craving models tested
ECs and ECLs Clinical Variables
Dietary Restraint Ovarian and
Satiety Hormones
Craving Carbs 0.058 0.904 0.935 0.374 Yes Fair
Craving sweets < 0.001 1.394 1.000 0.727 Yes Excellent
ECLs Clinical Variables Dietary
Restraint Ovarian and Satiety
Hormones
Craving Carbs < 0.001 3.340 1.000 0.919 Yes Excellent
Craving sweets 0.041 0.959 0.943 0.416 Yes Good
Fig. 2. Follicular phase SEM path diagram, depicting
role of endocannabinoids ovarian and satiety hor-
mones, clinical variables and eating behaviors in
craving sweet-tasting foods in the luteal phase in
n= 17 women. The boxes are measured variables,
circles are latent variables, and the final predictor
variable is craving (in this case - carbs). The width of
the colored arrows indicate the strength of the as-
sociation, grayed out arrows indicate no association,
and the double ended black arrows between the
(latent) circles indicate positive (solid lines) or in-
verse (dotted lines) covariance. This model was
identified with endocannabinoid like chemicals
(OEA), ovarian hormones (progesterone), and eating
behaviors (disinhibition) positively contributing to
craving carbohydrates. A < 0.001 RMSEA, with
1.000 CFI and 3.340 TLI, and p value of 0.919 in-
dicates excellent model fit.
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in the follicular phase appear to be associated with carbohydrate
craving and sweet-food craving. Progesterone concentrations peak
during the luteal phase [36] and have been shown to be associated with
increased cravings [37]. Interestingly, while progesterone appears to be
positively associated with craving carbohydrate and sweet-rich foods in
the presence of ECLs alone, adding ECs to the mix results in proges-
terone no longer being associated with craving sweet-rich foods. This
further strengthens our theory that ECs and ECLs together are capable
of influencing craving behaviors, likely even more than ovarian hor-
mones. Future studies, however, will be needed to confirm this in larger
samples, as well as by altering circulating ECs and ECLs and observing
their downstream effect on cravings.
To our knowledge, the current study is the first to compare the
postprandial insulinemic and glycemic responses between the two
phases in healthy young women. In the present study, even though
postprandial insulin was higher in the follicular phase, there were no
differences in glucose or HOMA-IR. If minor differences between the
two phases do exist in insulin sensitivity, as reported previously [38],
the present study did not identify them.
The concurrent luteal phase milieu was not successful at predicting
craving, but the follicular phase milieu was. There could be several
reasons for this. It may be likely that the milieu during the follicular
phase sets up women's physiology in the luteal phase that dictates
eating behavior. Alternatively, it could be due to the fact that we
captured women during their ovulation in the follicular phase, but the
luteal phase test occurred anytime in the mid to late luteal phase.
Estradiol peaks during the late follicular phase (Supplementary fig. 2),
drops during ovulation, and then peaks again in the mid-luteal phase,
while circulating progesterone concentrations during late-follicular/
ovulatory phase of the cycle match those of the last few days of the late-
luteal phase [39]. Studying women closer to the late-luteal phase may
identify stronger associations between circulating milieus and craving
behaviors, since most pre-menstrual syndrome symptoms (which may
include craving) are experienced during the latter part of the luteal
phase [40]. However, evidence about craving during the luteal phase
spans the entire luteal phase, and not only the late luteal phase [41],
especially since we did not target women with pre-menstrual syndrome
(PMS) in the present study. Future studies could choose women with
Fig. 3. Follicular phase SEM path diagram, depicting
role of endocannabinoids ovarian and satiety hor-
mones, clinical variables and eating behaviors in
craving sweet-tasting foods in the luteal phase in
n= 17 women. The boxes are measured variables,
circles are latent variables, and the final predictor
variable is craving (in this case - sweets).The width
of the colored arrows indicate the strength of the
association, grayed out arrows indicate no associa-
tion, and the double ended black arrows between the
(latent) circles indicate positive (solid lines) or in-
verse (dotted lines) covariance. This model was
identified with endocannabinoids (OEA) and eating
behaviors (disinhibition) positively contributing to
craving sweet foods, while ovarian hormones (pro-
gesterone) and clinical parameters (2hPP TG, 1hPP
HDL, 1hPP Glucose, Fasting glucose and HOMA-IR)
contributed inversely to craving sweet-foods. A
0.041 RMSEA, with 0.959 CFI and 0.943 TLI, and p
value of 0.416 indicates good model fit.
Fig. 4. Follicular phase SEM path diagram, depicting
role of endocannabinoids, ovarian and satiety hor-
mones, clinical variables and eating behavior in
craving sweet-tasting foods in the luteal phase in
n= 17 women. The boxes are measured variables,
circles are latent variables, and the final predictor
variable is craving (in this case - sweets).The width
of the colored arrows indicate the strength of the
association, grayed out arrows indicate no associa-
tion, and the double ended black arrows between the
(latent) circles indicate positive (solid lines) or in-
verse (dotted lines) covariance. This model was
identified with endocannabinoid like chemicals
(OEA), endocannabinoids (AEA), and clinical para-
meters (2 h PP TC) contributing positively to craving
sweet-foods. A < 0.001 RMSEA, with 1.000 CFI and
1.394 TLI, and p value of 0.727 indicates excellent
model fit.
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PMS and evaluate the same criteria.
4.1. Clinical implications of endocannabinoids, cravings and dietary fatty
acid composition
ECLs are structurally similar to ECs and they utilize the same bio-
synthesis and degradation pathways [30]. This enables an “entourage”
effect [42], an enhancement of the effect of ECs, by the presence of
these analogues (ECLs). They also inhibit degradation of ECs by com-
petitively binding with the degradation enzymes, or allosterically
modify binding of ECs to CB1/2 [43]. These could explain why our
models were best fit when using ECs and ECLs together. Furthermore,
both ECs and ECLs can be modulated by dietary fats. A dietary inter-
vention altering omega-3 and omega-6 PUFA recently has shown to
increase circulating ECs [44]. Diets high in palm, olive, safflower fish
and arachidonic acid have shown to differentially increase MAGs and
NAEs [44]. NAE's are synthesized from phosphatidylethanolamines
(phospholipids) using available fatty acids [30]. Dietary fatty acids
largely determine circulating NAEs, and increased oleic acid or linoleic
acid intake has shown downstream increases in OEA and LEA respec-
tively [45]. Hence, ECLs could be potential dietary targets to modulate
craving behaviors.
In the current study, NAEs, specifically OEA, was strongly asso-
ciated with carbohydrate craving, but inversely with sweet-food
craving. Since a mechanism exists for OEA to be satiety inducing, it is
likely that in women who struggle with body weight maintenance due
to sweet-food craving [46], modulating their dietary fat composition
during the follicular phase (i.e. increase olive oil intake, but decrease
long chain PUFA intake) may help modulate cravings.
4.2. Limitations
Our study sample size was small, and a larger study is needed to
confirm the findings from this report. Similarly, even though we
Fig. 5. A graphical representation of the proposed hypothetical metabolic-neuroendocrine framework involved in craving behaviors during the luteal phase of the
menstrual cycle in normal healthy women.
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thoroughly evaluated the quality and robustness of the SEM models, it
is still likely that the small sample size contributed to potential fallacies
in model development. SEM makes assumptions about linearity of
cause-effect associations between observed and predicted variables, as
well as between covariate relationships among them [47]. Simple re-
gression models assume this for a relationship between just one in-
dependent and dependent variable, while SEMs do this for all variables
involved, with increased “power” to predict a certain path. However, as
the objective was to probe different relationships under these assump-
tions to find out what may be hypothesized as potential causal path-
ways to further study, SEM was the ideal choice.
We also did not closely monitor the study participants' diet intake,
and knowledge of their intake of carbohydrates and sweet foods during
the luteal phase could have provided more insight into whether their
craving behaviors affected their intake. Our testing times for the men-
strual cycle phases could also have been repeated several times instead
of just twice, to give a more comprehensive view of the underlying
physiology. However, this is a first report on the associations between
circulating ECs, ECLs and craving behaviors in healthy women experi-
enced during the luteal phase of the menstrual cycle, and the ob-
servations are meaningful, albeit in a small group of women.
4.3. Conclusions
Our previous report identified luteal phase SHBG and estradiol/
leptin ratio to be positively associated with craving sweet-rich foods,
and leptin to be inversely associated with habitual sweet-rich food in-
take. Our current manuscript elaborates on these relationships, sug-
gesting associations between progesterone and craving while looking at
a more comprehensive picture by including the neuroendocrine sys-
tem's role (see Fig. 5). It is not surprising that including more variables
shed light on complex relationships that were previously undetected,
not to mention that SEM models benefit from more measured variables
representing their latent variables to better predict the outcome vari-
able [24]. In this study, the follicular phase metabolic and endocrine
milieu appears to be a better predictor of craving than the luteal phase
milieu. If we had measured craving during the follicular phase, we may
have been able to predict that based on luteal phase milieu. A future
study can evaluate whether there exists a cyclic feedback loop between
these phases with food intake affecting metabolic milieu that further
impacts craving and so on. OEA, progesterone and disinhibition are
positively associated with craving carbohydrates, while OEA and lipids
are inversely associated with craving sweet-rich foods, even though
progesterone retains its positive association. Finally, the influence of
these biological factors in craving indulging behaviors to result in in-
creased carbohydrate and sweet-rich food intake needs to be evaluated
further.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.physbeh.2018.07.011.
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